Employee Benefits and Stock Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation

The impact of share-based compensation on the Company’s financial results is presented below:

	For the Year Ended December 31,
(In thousands)	2023		2022		2021
Share-based compensation expense1	$	13,440	$	11,155	$	8,685
Income tax benefit	(3,406)		(2,827)		(2,067)
1 Excludes $10.3 million in 2023, $10.4 million in 2022 and $4.7 million in 2021 associated with replacement awards granted in bank acquisitions.

Schedule of Unrecognized Compensation Cost, Nonvested Awards

The total unrecognized compensation cost and the weighted-average period over which unrecognized compensation cost is expected to be recognized related to non-vested share-based compensation arrangements at December 31, 2023 is presented below:

(In thousands)	Unrecognized Compensation Cost		Weighted-Average Period Remaining (Years)
Restricted stock awards	$	14,392	1.94
Restricted stock units	5,636		2.30
Total	$	20,028	2.04

Schedule of Nonvested Share Activity

A summary of the status of the Company’s non-vested RSAs as of December 31, 2023, and changes during the year then ended, is presented below:

	Restricted Award Shares	Weighted-Average Grant-Date Fair Value
Non-vested at January 1, 2023	533,275	$	31.26
Granted	631,409	24.57
Forfeited/Canceled	(112,456)	27.35
Vested	(289,016)	28.22
Non-vested at December 31, 2023	763,212	$	27.45

A summary of the status of the Company’s non-vested RSUs as of December 31, 2023, and changes during the year then ended, is presented below:

	Restricted Award Shares	Weighted-Average Grant-Date Fair Value
Non-vested at January 1, 2023	310,034	$	28.69
Granted	233,175	22.84
Forfeited/Canceled	(47,416)	20.58
Vested	(112,092)	17.82
Non-vested at December 31, 2023	383,701	$	29.31

Schedule of Restricted Stock and Restricted Stock Units Activity

Information regarding restricted stock awards during each of the following years is presented below:

	For the Year Ended December 31,
	2023		2022		2021
Weighted-average grant date fair value	$	24.57	$	33.08	$	35.08
Fair value of awards vested1	$	8,156	$	6,923	$	4,731
1Based on grant date fair value, in thousands.

Information regarding restricted stock units during each of the following years is presented below:

	For the Year Ended December 31,
	2023		2022		2021
Weighted-average grant date fair value	$	22.84	$	34.11	$	35.24
Fair value of awards vested1	$	1,997	$	2,305	$	1,936
1Based on grant date fair value, in thousands.

Schedule of Stock Option Valuation Assumptions

	For the Year Ended December 31,
	2023		2022		2021
Risk-free interest rates	4.25	%	2.21	%	0.12	%
Expected dividend yield	2.45	%	1.95	%	1.65	%
Expected volatility	64.32	%	32.09	%	36.87	%
Expected lives (years)	1.8		1.0		1.0

Schedule of Stock Options Roll Forward

A summary of the Company’s stock options as of December 31, 2023, and changes during the year then ended, is presented below:

	Options		Weighted-Average Exercise Price
Outstanding at January 1, 2023	837,622		$	21.72
Granted in Acquisition	501,561		12.63
Exercised	(507,133)		14.76
Forfeited	(8,087)		20.77
Outstanding and Exercisable at December 31, 2023	823,963		$	20.48
Weighted-Average Remaining Contractual Term (Years)	3.29
Aggregate Intrinsic Value (000s)	$	7,053

Schedule of Stock Option Activity

The following table presents information related to stock options during each of the following years:

	For the Year Ended December 31,
	2023		2022		2021
Weighted-average grant date fair value	$	12.63	$	14.28	$	16.70
Intrinsic value of stock options exercised, in thousands	5,969		8,860		5,808

Schedule of Employee Stock Purchase Plan Activity

	2023		2022		2021
ESPP shares purchased	35,630		20,972		14,834
Weighted-average employee purchase price	$	22.56	$	30.76	$	32.43